Capitalize on Comeback Stories in Micro-Cap Biotech: Joe Pantginis of ROTH Capital Partners

The list of problems with investing in micro-cap biotech stocks begins with extreme volatility and lack of liquidity and ends with the inability to get validation from sophisticated investors who are unable to own such small companies.
Nevertheless, sift through the pile and investors can find gems. Joseph Pantginis of ROTH Capital Partners recognizes the characteristics that make some of these […]